High-dose therapy for follicular lymphoma revisited: Not if, but when?

Journal of Clinical Oncology

Volumn 21, Issue 21, 2003, Pages 3894-3896

  Lister, T Andrew ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CANCER VACCINE; CARMUSTINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; MONOCLONAL ANTIBODY; PREDNISONE; RITUXIMAB; VINCRISTINE; CHOP PROTOCOL;

AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; EDITORIAL; FOLLICULAR LYMPHOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LOW DRUG DOSE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT RESPONSE; WHOLE BODY RADIATION; CONTROLLED CLINICAL TRIAL; NOTE; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; LYMPHOMA, FOLLICULAR; PREDNISONE; RANDOMIZED CONTROLLED TRIALS; VINCRISTINE;

EID: 0642342668     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.07.981     Document Type: Editorial

References (43)

1. Galton DAG, Israels LG, Nabarro JDN, et al: Clinical trial of p (dichloroethylamino) phenylbutyric acid (CB1348) in malignant lymphoma. BMJ 2:1172-1176, 1955
2. Israels LG, Galton DAG, Till M, et al: Clinical evaluation of CB1348 in malignant lymphoma and related diseases. Ann NY Acad Sci 68:915-925, 1958
3. Hoogstraten B, Owens AH, Lenhard RE, et al: Combination chemotherapy in lymphosarcoma and reticulum cell sarcoma. Blood 33:370-378, 1969
4. Portlock CS, Rosenberg SA, Glatstein E, et al: Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: Preliminary results of a prospective trial. Blood 47:747-756, 1976
5. Lister TA, Cullen MH, Beard ME, et al: Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. BMJ 1:533-537, 1978
6. Kennedy BJ, Bloomfield CD, Kiang DT, et al: Combination versus successive single agent chemotherapy in lymphocytic lymphoma. Cancer 41:23-28, 1978
7. Hoppe RT, Kushlan P, Kaplan HS, et al: The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomized trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 58:592-598, 1981
8. Ezdinli E, Anderson JR, Melvin F, et al: Moderate versus aggressive chemotherapy of nodular poorly differentiated lymphoma. J Clin Oncol 3:769-775, 1985
9. Steward WP, Crowther D, McWilliam LJ, et al: Maintenance chlorambucil after CVP in the management of advanced stage, low-grade histologic type non-Hodgkin's lymphoma. A randomized prospective study with an assessment of prognostic factors. Cancer 61:441-447, 1988
10. Peterson BA, Petroni GR, Frizzera G, et al: Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 21:5-15, 2003
11. Lopez-Guillermo A, Cabanillas F, McLaughlin P, et al: Molecular response assessed by PCR is the most important factor predicting failure free survival in indolent follicular lymphoma: update of the MDACC series. Ann Oncol 11:137-140, 2000 (suppl 1)
12. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
13. Schouten HC, Bierman PJ, Vaughan WP, et al: Autologous bone marrow transplantation in follicular non-Hodgkin's lymphoma before and after histologic transformation. Blood 74:2579-2584, 1989
14. Freedman AS, Neuberg D, Mauch P, et al: Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 94:3325-3333, 1999
15. Rohatiner AZ, Johnson PW, Price CG, et al: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 12:1177-1184, 1994
16. Apostolidis J, Foran JM, Johnson PW, et al: Patterns of outcome following recurrence after myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 17:216-221, 1999
17. Apostolidis J, Gupta RK, Grenzelias D, et al: High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long term clinical and molecular follow-up J Clin Oncol 18:527-536, 2000
18. Bastion Y, Brice P, Haioun C, et al: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor prognosis follicular lymphoma. Blood 86:3257-3262, 1995
19. Haas R, Moos M, Mohle R, et al: High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Bone Marrow Transplant 17:149-155, 1996
20. Freedman AS, Gribben JG, Neuberg D, et al: High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 88:2780-2786, 1996
21. Horning SJ, Negrin RS, Hoppe RT, et al: High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood 97:404-409, 2001
22. Bierman PJ, Vose JM, Anderson JR, et al: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 15:445-450, 1997
23. Tarella C, Corradini P, Caracciolo D, et al: High dose chemotherapy as upfront treatment in 35 patients with indolent lymphoma induces a high rate of durable clinical and molecular remission. Leukaemia 14:740-747, 2000
24. Micallef IN, Lillington DM, Apostolidis J, et al: Therapy-related myelodysplasia and secondary acute myelogenous leukemia following high-dose therapy with autologous hematopoeitic progenitor cell support for lymphoid malignancies. J Clin Oncol 18:947-955, 2000
25. Darrington DL, Vose JM, Anderson JR, et al: Incidence and characterization of secondary myelodysplasia syndrome following high-dose, chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 12:2527-2534, 1994
26. Miller J, Arthur D, Litz C, et al: Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 83:3780-3786, 1994
27. Stone R, Neuberg D, Soiffer R, et al: Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 12:2535-2542, 1994
28. Friedberg JW, Neuberg D, Stone RM, et al: Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 17:3128-3135, 1999
29. Milligan DW, Ruiz de Elvira MC, Kolb HJ, et al: Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. EBMT Lymphoma and Late Effects Working Parties. European Group for Blood and Marrow Transplantation. Br J Haematol 106:1020-1026, 1999
30. Schouten HC, Qian W, Kvaloy S, et al: High dose therapy improves progression free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 21:3918-3927, 2003
31. Sebban C, Coiffier B, Brice P, et al: A randomised trial in follicular lymphoma comparing a standard chemotherapy regimen with four courses of CHOP following by autologous stem cell transplant with TBI: the GELF 94 trial from GELA. Hematol J 4:150, 2003 (suppl 2, abstr 0486)
32. Solal-Celigny P, Lepage E, Brousse N, et al: Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med 329:1608-1614, 1993
33. Rohatiner A, Gregory W, Peterson B, et al: A meta analysis of randomized studies evaluation the role of interferon alpha as treatment for follicular lymphoma. J Clin Oncol 20:264a, 2002 (abstr 1053)
34. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al: IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 15:3266-3274, 1997
35. Foran JM, Gupta RK, Cunningham D, et al: A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response. Br J Haematol 109:81-88, 2000
36. Cartron G, Dacheux L, Salles G, et al: Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99:754-758, 2002
37. Czuczman MS, Grillo-Lopez AJ, White CA, et al: Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268-276, 1999
38. Kaminski MS, Zelenetz AD, Press OW, et al: Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphoma. J Clin Oncol 19:3918-3928, 2001
39. Witzig TE, Gordon LI, Cabanillas F, et al: Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453-2463, 2002
40. Press OW, Eary JF, Gooley T, et al: A phase I/II trial of iodine-131-tositumomab (anti-CD20) etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 96:2934-2942, 2000
41. Slavin S, Nagler A, Naparstek E, et al: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756-763, 1998
42. Khouri IF, Saliba RM, Giralt SA, et al: Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 98:3595-3599, 2001
43. Solal-Celigny P. The Follicular Lymphoma Prognostic Project. International Prognostic Index (PI) for follicular lymphoma (FL). J Clin Oncol 21:281a, 2002 (abstr 1121)